Abstract
Bladder-sparing trimodality therapy (TMT) as an acceptable alternative to radical cystectomy (RC) for the treatment of muscle invasive bladder cancer (MIBC) is the product of consecutive institutional and national protocols over decades and across continents. RC and TMT are now recognized as bona fide treatment options for MIBC by multiple international guidelines. 1 Chang SS et al. Treatment of non-metastatic muscle-invasive bladder cancer: AUA/ASCO/ASTRO/SUO guideline. J Urol. 2017; 198: 552-559 Crossref PubMed Scopus (473) Google Scholar , 2 Alfred Witjes J et al. Updated 2016 EAU guidelines on muscle-invasive and metastatic bladder cancer. Eur Urol. 2017; 71: 462-475 Abstract Full Text Full Text PDF PubMed Scopus (1066) Google Scholar
Published Version
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a call